Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8832328 | 0.88 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2DPP4CYP2A13HPGD | |
| SCHEMBL16878611 | 0.77 | DPP4 (0.35) | ALDH1A1SMN1; SMN2DPP4 | |
| SCHEMBL7561952 | 0.74 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL26112782 | 0.73 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2CYP2A13HPGDL3MBTL3 | |
| SCHEMBL26112778 | 0.73 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2CYP2A13HPGDL3MBTL3 | |
| SCHEMBL3168997 | 0.73 | — | — | |
| SCHEMBL16877376 | 0.72 | — | — | |
| Ammonia Solution, Strong SCHEMBL4295582 | 0.71 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2CYP2A13HPGDL3MBTL3 | |
| SCHEMBL14862483 | 0.71 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2CYP2A13HPGDL3MBTL3 | |
| SCHEMBL9425142 | 0.69 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2CYP2A13HPGDL3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2011-07-28 | — | — | US | disclosed |
| EP-2318400-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010013037-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | SHH, SMO, GLI1 | ALDH1A1 663/4885SMN1; SMN2 518/4885DPP4 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.